未经证实:神经内分泌瘤(NEN)的发病率在国际上呈上升趋势。我们旨在评估NEN在英格兰的流行病学,并检查生存率随时间的变化。
未经评估:回顾,使用1995年至2018年英格兰国家癌症登记和分析服务(NCRAS)的全国代表性数据,对63,949例肿瘤进行了基于人群的研究.使用国家统计局(ONS)数据计算年龄标准化的发病率。使用Kaplan-Meier估计器计算总生存期(OS)。使用加速故障时间模型进行多变量分析。
未经评估:在63,949例中,50.5%(32,309)为女性。从1995年到2018年,年龄调整后的发病率增加了3.7倍,从每10万人2.35增至8.61。2018年,肺部发病率最高(1.47/10万),小肠(1.46/100,000),胰腺(每100,0001.00)和阑尾(每100,0000.95)。在多变量分析中,年龄,性别,形态学,舞台,站点和剥夺是生存的独立预测因子(p<0.001)。整个队列的生存,按主站点,随着时间的推移正在改善。
UNASSIGNED:NEN发病率在英格兰持续上升,生存率随着时间的推移而提高。与其他癌症相比,相对较高的生存率是长期结果和护理资金的问题。
UNASSIGNED:使用英国神经内分泌癌症的资助提取和转移数据。
UNASSIGNED: Neuroendocrine neoplasia (NEN) incidence is rising internationally. We aimed to evaluate the epidemiology of NEN in England and examine changes in survival over time.
UNASSIGNED: A retrospective, population-based
study using nationally representative data between 1995 and 2018 from the National Cancer Registry and Analysis Service (NCRAS) in England was conducted on 63,949 tumours. Age-standardized incidence was calculated using Office for National Statistics (ONS) data. Overall survival (OS) was calculated using the Kaplan-Meier estimator. Multivariable analysis was performed using an accelerated failure time model.
UNASSIGNED: Of 63,949 cases, 50.5% (32,309) were female. Age-adjusted incidence increased 3.7-fold between 1995 and 2018 from 2.35 to 8.61 per 100,000. In 2018, highest incidence occurred in lung (1.47 per 100,000), small intestine (1.46 per 100,000), pancreas (1.00 per 100,000) and appendix (0.95 per 100,000). In multivariable analysis, age, sex, morphology, stage, site and deprivation were independent predictors of survival (p < 0.001). Survival of the entire cohort, and by primary site, is improving over time.
UNASSIGNED: NEN incidence continues to rise in England with survival improving over time. Relatively high survival compared to other cancers is an issue for long-term outcomes and funding of care.
UNASSIGNED: Data were extracted and transferred using a grant from Neuroendocrine cancer UK.